KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Other financing activities (2017 - 2025)

Exact Sciences (EXAS) has disclosed Other financing activities for 9 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 21.76% to -$1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.9 million, a 33.05% increase, with the full-year FY2025 number at -$11.9 million, up 33.05% from a year prior.
  • Other financing activities was -$1.7 million for Q4 2025 at Exact Sciences, up from -$1.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$417000.0 in Q4 2022 to a low of -$11.6 million in Q2 2024.
  • A 5-year average of -$2.5 million and a median of -$1.7 million in 2021 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: plummeted 903.64% in 2024, then skyrocketed 84.13% in 2025.
  • Exact Sciences' Other financing activities stood at -$544000.0 in 2021, then grew by 23.35% to -$417000.0 in 2022, then plummeted by 443.65% to -$2.3 million in 2023, then grew by 2.51% to -$2.2 million in 2024, then increased by 21.76% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Other financing activities are -$1.7 million (Q4 2025), -$1.7 million (Q3 2025), and -$1.8 million (Q2 2025).